Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 21

Publication Record


Glutamate-oxaloacetate transaminase activity promotes palmitate lipotoxicity in rat hepatocytes by enhancing anaplerosis and citric acid cycle flux.
Egnatchik RA, Leamy AK, Sacco SA, Cheah YE, Shiota M, Young JD
(2019) J Biol Chem 294: 3081-3090
MeSH Terms: Animals, Aspartate Aminotransferases, Cell Death, Cell Line, Citric Acid Cycle, Extracellular Space, Glutamine, Hepatocytes, Ketoglutaric Acids, Male, Oxidative Stress, Oxygen, Palmitates, Rats, Rats, Sprague-Dawley
Show Abstract · Added March 28, 2019
Hepatocyte lipotoxicity is characterized by aberrant mitochondrial metabolism, which predisposes cells to oxidative stress and apoptosis. Previously, we reported that translocation of calcium from the endoplasmic reticulum to mitochondria of palmitate-treated hepatocytes activates anaplerotic flux from glutamine to α-ketoglutarate (αKG), which subsequently enters the citric acid cycle (CAC) for oxidation. We hypothesized that increased glutamine anaplerosis fuels elevations in CAC flux and oxidative stress following palmitate treatment. To test this hypothesis, primary rat hepatocytes or immortalized H4IIEC3 rat hepatoma cells were treated with lipotoxic levels of palmitate while modulating anaplerotic pathways leading to αKG. We found that culture media supplemented with glutamine, glutamate, or dimethyl-αKG increased palmitate lipotoxicity compared with media that lacked these anaplerotic substrates. Knockdown of glutamate-oxaloacetate transaminase activity significantly reduced the lipotoxic effects of palmitate, whereas knockdown of glutamate dehydrogenase (Glud1) had no effect on palmitate lipotoxicity. C flux analysis of H4IIEC3 cells co-treated with palmitate and the pan-transaminase inhibitor aminooxyacetic acid confirmed that reductions in lipotoxic markers were associated with decreases in anaplerosis, CAC flux, and oxygen consumption. Taken together, these results demonstrate that lipotoxic palmitate treatments enhance anaplerosis in cultured rat hepatocytes, causing a shift to aberrant transaminase metabolism that fuels CAC dysregulation and oxidative stress.
© 2019 Egnatchik et al.
0 Communities
1 Members
0 Resources
15 MeSH Terms
High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, Brown NJ
(2016) JAMA 315: 877-88
MeSH Terms: Acute Kidney Injury, Aged, Aged, 80 and over, Aspartate Aminotransferases, Atorvastatin, Cardiac Surgical Procedures, Creatinine, Double-Blind Method, Drug Administration Schedule, Female, Glomerular Filtration Rate, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Medication Adherence, Middle Aged, Postoperative Complications, Renal Insufficiency, Chronic
Show Abstract · Added April 6, 2017
IMPORTANCE - Statins affect several mechanisms underlying acute kidney injury (AKI).
OBJECTIVE - To test the hypothesis that short-term high-dose perioperative atorvastatin would reduce AKI following cardiac surgery.
DESIGN, SETTING, AND PARTICIPANTS - Double-blinded, placebo-controlled, randomized clinical trial of adult cardiac surgery patients conducted from November 2009 to October 2014 at Vanderbilt University Medical Center.
INTERVENTIONS - Patients naive to statin treatment (n = 199) were randomly assigned 80 mg of atorvastatin the day before surgery, 40 mg of atorvastatin the morning of surgery, and 40 mg of atorvastatin daily following surgery (n = 102) or matching placebo (n = 97). Patients already taking a statin prior to study enrollment (n = 416) continued taking the preenrollment statin until the day of surgery, were randomly assigned 80 mg of atorvastatin the morning of surgery and 40 mg of atorvastatin the morning after (n = 206) or matching placebo (n = 210), and resumed taking the previously prescribed statin on postoperative day 2.
MAIN OUTCOMES AND MEASURES - Acute kidney injury defined as an increase of 0.3 mg/dL in serum creatinine concentration within 48 hours of surgery (Acute Kidney Injury Network criteria).
RESULTS - The data and safety monitoring board recommended stopping the group naive to statin treatment due to increased AKI among these participants with chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73 m2) receiving atorvastatin. The board later recommended stopping for futility after 615 participants (median age, 67 years; 188 [30.6%] were women; 202 [32.8%] had diabetes) completed the study. Among all participants (n = 615), AKI occurred in 64 of 308 (20.8%) in the atorvastatin group vs 60 of 307 (19.5%) in the placebo group (relative risk [RR], 1.06 [95% CI, 0.78 to 1.46]; P = .75). Among patients naive to statin treatment (n = 199), AKI occurred in 22 of 102 (21.6%) in the atorvastatin group vs 13 of 97 (13.4%) in the placebo group (RR, 1.61 [0.86 to 3.01]; P = .15) and serum creatinine concentration increased by a median of 0.11 mg/dL (10th-90th percentile, -0.11 to 0.56 mg/dL) in the atorvastatin group vs by a median of 0.05 mg/dL (10th-90th percentile, -0.12 to 0.33 mg/dL) in the placebo group (mean difference, 0.08 mg/dL [95% CI, 0.01 to 0.15 mg/dL]; P = .007). Among patients already taking a statin (n = 416), AKI occurred in 42 of 206 (20.4%) in the atorvastatin group vs 47 of 210 (22.4%) in the placebo group (RR, 0.91 [0.63 to 1.32]; P = .63).
CONCLUSIONS AND RELEVANCE - Among patients undergoing cardiac surgery, high-dose perioperative atorvastatin treatment compared with placebo did not reduce the risk of AKI overall, among patients naive to treatment with statins, or in patients already taking a statin. These results do not support the initiation of statin therapy to prevent AKI following cardiac surgery.
TRIAL REGISTRATION - clinicaltrials.gov Identifier: NCT00791648.
0 Communities
1 Members
0 Resources
18 MeSH Terms
Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME, TB Trials Consortium
(2015) Int J Tuberc Lung Dis 19: 1039-44, i-v
MeSH Terms: Adult, Antitubercular Agents, Aspartate Aminotransferases, Brazil, Canada, Case-Control Studies, Chemical and Drug Induced Liver Injury, Drug Administration Schedule, Drug Therapy, Combination, Female, Hepatitis C, Humans, Isoniazid, Latent Tuberculosis, Male, Middle Aged, Multivariate Analysis, Rifampin, Risk Factors, Spain, United States
Show Abstract · Added February 17, 2016
SETTING - Nine months of daily isoniazid (9H) and 3 months of once-weekly rifapentine plus isoniazid (3HP) are recommended treatments for latent tuberculous infection (LTBI). The risk profile for 3HP and the contribution of hepatitis C virus (HCV) infection to hepatotoxicity are unclear.
OBJECTIVES - To evaluate the hepatotoxicity risk associated with 3HP compared to 9H, and factors associated with hepatotoxicity.
DESIGN - Hepatotoxicity was defined as aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN) with symptoms (nausea, vomiting, jaundice, or fatigue), or AST >5 x ULN. We analyzed risk factors among adults who took at least 1 dose of their assigned treatment. A nested case-control study assessed the role of HCV.
RESULTS - Of 6862 participants, 77 (1.1%) developed hepatotoxicity; 52 (0.8%) were symptomatic; 1.8% (61/3317) were on 9H and 0.4% (15/3545) were on 3HP (P < 0.0001). Risk factors for hepatotoxicity were age, female sex, white race, non-Hispanic ethnicity, decreased body mass index, elevated baseline AST, and 9H. In the case-control study, HCV infection was associated with hepatotoxicity when controlling for other factors.
CONCLUSION - The risk of hepatotoxicity during LTBI treatment with 3HP was lower than the risk with 9H. HCV and elevated baseline AST were risk factors for hepatotoxicity. For persons with these risk factors, 3HP may be preferred.
0 Communities
1 Members
0 Resources
21 MeSH Terms
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
Phillips E, Bartlett JA, Sanne I, Lederman MM, Hinkle J, Rousseau F, Dunn D, Pavlos R, James I, Mallal SA, Haas DW
(2013) J Acquir Immune Defic Syndr 62: e55-7
MeSH Terms: Adult, Alanine Transaminase, Anti-HIV Agents, Aryl Hydrocarbon Hydroxylases, Aspartate Aminotransferases, Chemical and Drug Induced Liver Injury, Cytochrome P-450 CYP2B6, Double-Blind Method, Female, Genotype, HIV Infections, HLA-B Antigens, HLA-DRB1 Chains, Humans, Male, Multivariate Analysis, Nevirapine, Oxidoreductases, N-Demethylating, Phenotype, Reverse Transcriptase Inhibitors, South Africa
Added March 13, 2015
0 Communities
1 Members
0 Resources
21 MeSH Terms
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis.
Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ, NA-ACCORD and VACS Project Teams
(2013) J Acquir Immune Defic Syndr 62: 149-63
MeSH Terms: Age Factors, Alanine Transaminase, Anti-Retroviral Agents, Aspartate Aminotransferases, Biomarkers, CD4 Lymphocyte Count, Cohort Studies, Creatinine, Female, HIV Infections, HIV-1, Hemoglobins, Hepatitis C, Humans, Kaplan-Meier Estimate, Male, Middle Aged, North America, Platelet Count, Predictive Value of Tests, RNA, Viral, Risk Assessment, Sex Factors
Show Abstract · Added May 29, 2014
BACKGROUND - By supplementing an index composed of HIV biomarkers and age (restricted index) with measures of organ injury, the Veterans Aging Cohort Study (VACS) index more completely reflects risk of mortality. We compare the accuracy of the VACS and restricted indices (1) among subjects outside the Veterans Affairs Healthcare System, (2) more than 1-5 years of prior exposure to antiretroviral therapy (ART), and (3) within important patient subgroups.
METHODS - We used data from 13 cohorts in the North American AIDS Cohort Collaboration (n = 10, 835) limiting analyses to HIV-infected subjects with at least 12 months exposure to ART. Variables included demographic, laboratory (CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine transaminase, creatinine, and hepatitis C status), and survival. We used C-statistics and net reclassification improvement (NRI) to test discrimination varying prior ART exposure from 1 to 5 years. We then combined Veterans Affairs Healthcare System (n = 5066) and North American AIDS Cohort Collaboration data, fit a parametric survival model, and compared predicted to observed mortality by cohort, gender, age, race, and HIV-1 RNA level.
RESULTS - Mean follow-up was 3.3 years (655 deaths). Compared with the restricted index, the VACS index showed greater discrimination (C-statistics: 0.77 vs. 0.74; NRI: 12%; P < 0.0001). NRI was highest among those with HIV-1 RNA <500 copies per milliliter (25%) and age ≥50 years (20%). Predictions were similar to observed mortality among all subgroups.
CONCLUSIONS - VACS index scores discriminate risk and translate into accurate mortality estimates over 1-5 years of exposure to ART and for diverse patient subgroups from North American.
0 Communities
1 Members
0 Resources
23 MeSH Terms
An internationally generalizable risk index for mortality after one year of antiretroviral therapy.
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA
(2013) AIDS 27: 563-72
MeSH Terms: Adult, Age Factors, Aged, Alanine Transaminase, Anti-HIV Agents, Aspartate Aminotransferases, Biomarkers, CD4 Lymphocyte Count, Cohort Studies, Europe, Female, HIV Infections, Hemoglobins, Hepatitis C, Humans, Male, Middle Aged, Multiple Organ Failure, Platelet Count, Predictive Value of Tests, RNA, Viral, Risk Assessment, United States
Show Abstract · Added May 29, 2014
OBJECTIVE - Despite the success of antiretroviral therapy (ART), excess mortality continues for those with HIV infection. A comprehensive approach to risk assessment, addressing multiorgan system injury on ART, is needed. We sought to develop and validate a practical and generalizable mortality risk index for HIV-infected individuals on ART.
DESIGN AND METHODS - The Veterans Aging Cohort Study (VACS) was used to develop the VACS Index, based on age, CD4 cell count, HIV-1 RNA, hemoglobin, aspartate and alanine transaminase, platelets, creatinine and hepatitis C status, and a Restricted Index based on age, CD4 cell count and HIV-1 RNA with an outcome of death up to 6 years after ART initiation. Validation was in six independent cohorts participating in the ART Cohort Collaboration (ART-CC).
RESULTS - In both the development (4932 patients, 656 deaths) and validation cohorts (3146 patients, 86 deaths) the VACS Index had better discrimination than the Restricted Index (c-statistics 0.78 and 0.72 in VACS, 0.82 and 0.78 in ART-CC). The VACS Index also demonstrated better discrimination than the Restricted Index for HIV deaths and non-HIV deaths, in men and women, those younger and older than 50 years, with and without detectable HIV-1 RNA, and with or without HCV coinfection.
CONCLUSIONS - Among HIV-infected patients treated with ART, the VACS Index more accurately discriminates mortality risk than traditional HIV markers and age alone. By accounting for multiorgan system injury, the VACS Index may prove a useful tool in clinical care and research.
0 Communities
1 Members
0 Resources
23 MeSH Terms
Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C.
Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y
(2011) Cancer Epidemiol Biomarkers Prev 20: 2204-11
MeSH Terms: ADAM Proteins, ADAMTS13 Protein, Aged, Alanine Transaminase, Aspartate Aminotransferases, Biomarkers, Tumor, Blood Proteins, Carcinoma, Hepatocellular, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Hepacivirus, Hepatic Stellate Cells, Hepatitis B virus, Hepatitis B, Chronic, Hepatitis C, Chronic, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis
Show Abstract · Added May 2, 2014
BACKGROUND - Chronic liver injury evokes a wound healing response, promoting fibrosis and finally hepatocellular carcinoma (HCC), in which hepatic stellate cells play an important role. Although a blood marker of hepatic stellate cells is not known, those cells importantly contribute to the regulation of plasma a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity, a defect of which causes thrombotic thrombocytopenic purpura.
METHODS - Plasma ADAMTS13 was evaluated in chronic hepatitis B or C patients with or without HCC.
RESULTS - Plasma ADAMTS13 activity significantly correlated with serum aspartate aminotransferase and alanine aminotransferase, liver stiffness value, and aspartate aminotransferase-to-platelet ratio index, irrespective of the presence of HCC, suggesting that it may reflect hepatocellular damage and subsequent wound healing and fibrosis as a result of hepatic stellate cell action. During the three-year follow-up period for patients without HCC, it developed in 10 among 81 patients. Plasma ADAMTS13 activity was significantly higher in patients with HCC development than in those without and was a significant risk for HCC development by univariate and multivariate analyses. Furthermore, during the one-year follow-up period for patients with HCC treated with radiofrequency ablation, HCC recurred in 55 among 107 patients. Plasma ADAMTS13 activity or antigen level was significantly higher in patients with HCC recurrence than in those without and was retained as a significant risk for HCC recurrence by multivariate analysis.
CONCLUSIONS - Higher plasma ADAMTS13 activity and antigen level was a risk of HCC development in chronic liver disease.
IMPACT - Plasma ADAMTS13 as a potential marker of hepatic stellate cells may be useful in the prediction of hepatocarcinogenesis.
©2011 AACR
0 Communities
1 Members
0 Resources
23 MeSH Terms
Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.
Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Bar Ad V, Eschelman DJ, Parker L, Doyle LA, Brown DB
(2011) J Vasc Interv Radiol 22: 1373-9
MeSH Terms: Adult, Aged, Aged, 80 and over, Alanine Transaminase, Aspartate Aminotransferases, Bilirubin, Biomarkers, Embolization, Therapeutic, Female, Humans, Incidence, Liver Diseases, Liver Function Tests, Liver Neoplasms, Male, Middle Aged, Philadelphia, Radiation Injuries, Radiopharmaceuticals, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Young Adult, Yttrium Radioisotopes
Show Abstract · Added March 5, 2014
PURPOSE - To report the incidence of liver function test (LFT) toxicities after radioembolization with yttrium-90 ((90)Y) SIR-Spheres and review potential risk factors.
MATERIALS AND METHODS - Patients receiving (90)Y for radioembolization of primary or metastatic liver tumors had follow-up LFTs 29-571 days after treatment. The incidence and duration of bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) toxicities were documented using common terminology criteria. Factors that were assessed included previous intra-arterial (IA) therapy, systemic chemotherapy, low tumor-to-normal liver tissue ratio at mapping angiography, vascular stasis, and higher prescribed (90)Y doses.
RESULTS - There were 81 patients who underwent 122 infusions and had follow-up LFTs. Of 122 infusions, 71 (58%) were associated with toxicity. One patient died with radiation-induced liver disease. Grade 3 or greater toxicities occurred in seven (7%) patients after nine procedures. The median durations of laboratory elevations for bilirubin, AST, and ALT were 29 days, 29 days, and 20 days. Toxicity developed after 51 (71%) of 72 infusions with previous IA therapy versus 20 (40%) of 50 infusions in treatment-naïve areas (P = .0006). Absence of previous systemic therapy was associated with greater risk of toxicity versus previous chemotherapy (47% vs 66%, P = .03). Other factors were not associated with increased toxicity.
CONCLUSIONS - Mild hepatotoxicity developed frequently after infusion of SIR-Spheres using the body surface area method, with normalization of LFTs in most patients. Grade 3 or greater toxicities were seen in < 10% of infusions. Toxicity was strongly associated with previous IA therapy.
Copyright © 2011 SIR. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
26 MeSH Terms
Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men.
Villegas R, Xiang YB, Elasy T, Cai Q, Xu W, Li H, Fazio S, Linton MF, Raiford D, Zheng W, Shu XO
(2011) Metab Syndr Relat Disord 9: 305-11
MeSH Terms: Adult, Aged, Alanine Transaminase, Asian Continental Ancestry Group, Aspartate Aminotransferases, China, Cohort Studies, Diabetes Mellitus, Type 2, Humans, Liver, Male, Metabolic Syndrome, Middle Aged, Motor Activity, Prevalence, Urban Population
Show Abstract · Added December 10, 2013
BACKGROUND - We examined associations between elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) with physical activity and obesity measures in middle-aged urban Chinese men. The associations between elevated aminotransferases with impaired fasting glucose, newly diagnosed type 2 diabetes (T2D), and metabolic syndrome were also evaluated in this population.
METHODS - The study included 3,978 urban Chinese men 40-74 years of age from a population-based cohort study, the Shanghai Men's Health Study, who were free of T2D at baseline and had provided fasting blood samples. Elevated AST and ALT levels were defined as >40 U/L. Anthropometric measurements and information on lifestyle factors and disease history were collected by in-person interviews.
RESULTS - A total of 11.13% and 5.85% study participants had elevated serum ALT and AST levels, respectively. Both body mass index (BMI) and waist-to-hip ratio (WHR) were positively associated with elevated ALT and AST. We found stronger associations between ALT and BMI/WHR than between AST and BMI/WHR. Physical activity was inversely associated with ALT and AST, but the association was attenuated after adjustment for BMI and WHR. Elevated serum aminotransferase levels were associated with T2D and metabolic syndrome.
CONCLUSIONS - In this representative sample of middle-aged Chinese men, elevated ALT and AST were associated with a prevalence of metabolic syndrome and T2D. These findings suggest that the relationship between obesity and T2D might involve liver injury. Physical activity might reduce the levels of ALT and AST, probably mediated through weight reduction.
0 Communities
3 Members
0 Resources
16 MeSH Terms
2-APB protects against liver ischemia-reperfusion injury by reducing cellular and mitochondrial calcium uptake.
Nicoud IB, Knox CD, Jones CM, Anderson CD, Pierce JM, Belous AE, Earl TM, Chari RS
(2007) Am J Physiol Gastrointest Liver Physiol 293: G623-30
MeSH Terms: Alanine Transaminase, Animals, Aspartate Aminotransferases, Boron Compounds, Calcium, Calcium Channel Blockers, Calcium Radioisotopes, Cell Death, Cell Line, Tumor, Cytochromes c, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, L-Lactate Dehydrogenase, Liver, Male, Mitochondria, Liver, Mitochondrial Membranes, Permeability, Rats, Rats, Sprague-Dawley, Recombinant Fusion Proteins, Reperfusion Injury, Time Factors, Transfection
Show Abstract · Added January 10, 2014
Ischemia-reperfusion (I/R) injury is a commonly encountered clinical problem in liver surgery and transplantation. The pathogenesis of I/R injury is multifactorial, but mitochondrial Ca(2+) overload plays a central role. We have previously defined a novel pathway for mitochondrial Ca(2+) handling and now further characterize this pathway and investigate a novel Ca(2+)-channel inhibitor, 2-aminoethoxydiphenyl borate (2-APB), for preventing hepatic I/R injury. The effect of 2-APB on cellular and mitochondrial Ca(2+) uptake was evaluated in vitro by using (45)Ca(2+). Subsequently, 2-APB (2 mg/kg) or vehicle was injected into the portal vein of anesthetized rats either before or following 1 h of inflow occlusion to 70% of the liver. After 3 h of reperfusion, liver injury was assessed enzymatically and histologically. Hep G2 cells transfected with green fluorescent protein-tagged cytochrome c were used to evaluate mitochondrial permeability. 2-APB dose-dependently blocked Ca(2+) uptake in isolated liver mitochondria and reduced cellular Ca(2+) accumulation in Hep G2 cells. In vivo I/R increased liver enzymes 10-fold, and 2-APB prevented this when administered pre- or postischemia. 2-APB significantly reduced cellular damage determined by hematoxylin and eosin and terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling staining of liver tissue. In vitro I/R caused a dissociation between cytochrome c and mitochondria in Hep G2 cells that was prevented by administration of 2-APB. These data further establish the role of cellular Ca(2+) uptake and subsequent mitochondrial Ca(2+) overload in I/R injury and identify 2-APB as a novel pharmacological inhibitor of liver I/R injury even when administered following a prolonged ischemic insult.
0 Communities
1 Members
0 Resources
25 MeSH Terms